Latest Insider Transactions at Dexcom Inc (DXCM)
This section provides a real-time view of insider transactions for Dexcom Inc (DXCM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of DEXCOM INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of DEXCOM INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 23
2020
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.25%
|
$434,837
$403.66 P/Share
|
|
Oct 15
2020
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
1,000
-1.35%
|
$395,000
$395.73 P/Share
|
|
Oct 14
2020
|
Richard Doubleday EVP Chief Commercial Officer |
BUY
Other acquisition or disposition
|
Indirect |
13,313
+50.0%
|
-
|
|
Oct 14
2020
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Other acquisition or disposition
|
Direct |
13,313
-28.44%
|
-
|
|
Oct 11
2020
|
Kyle Malady Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,272
+50.0%
|
-
|
|
Oct 01
2020
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
200
-0.32%
|
$84,000
$420.0 P/Share
|
|
Sep 30
2020
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
2,000
-1.54%
|
$820,000
$410.69 P/Share
|